Brind.

Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.

Steady: 0 in the last 7 days Updated oct 31

The latest in this situation

  1. The U.S. market saw nearly 50% growth amid generic competition, while China faced volume-based procurement impacts on new drug regimens.

How it started

2 reports, 2 independent, last reported Aug 13. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.

Who's involved

What this event is mainly about
ChinaBioPharmaBruker

How it developed

Newest first. Tap a step to see who reported it.
  1. Agilent is discussing revenue growth due to stable demand and biopharma recovery, while also noting how tariff concerns are impacting order trends in China.Sub-event
  2. Slowdown in pharmaceutical spending in China is impacting companies like Novartis, with potential effects from US generic market entries.Sub-event
  3. Bruker and Humana are facing soft demand from academic institutions and a slowdown in the biopharma market.Sub-event
  4. Richard Tobin cited positive margin mix from growth platforms for BioPharma.Sub-event
  5. Penumbra is facing growth impacts due to uncertainties regarding FDA review timelines and revenue decline in China.Sub-event
  6. Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.Sub-event
  7. Tariffs and China's slow stimulus are causing caution and delaying biopharma investments.1 source
  8. Biopharma market faces challenging demand but shows signs of recovery in drug discovery.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStoryBRKR Q2 Deep Dive: Funding and Tariff Headwinds Drive Guidance Cuts, Cost Actions Accelerate Scientific instrument company Bruker (NASDAQ:BRKR). missed Wall Street’s revenue expectations in Q2 CY2025
  • Business WireBruker Reports Second Quarter 2025 Financial Results Q2 2025 revenues of $797.4 million, down 0.4% year-over-year (yoy); organic revenue down 7.0%, and constant-exchange rate (CER) revenue down 3.3%